Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC.
Biochem Pharmacol. 2011 Jan 15;81(2):269-78. doi: 10.1016/j.bcp.2010.10.007. Epub 2010 Oct 20.
A selective phospholipase D (PLD) inhibitor 5-fluoro-2-indolyl des-chlorohalopemide (FIPI) inhibited the O(2)(-) generation and cell migration but not degranulation in formyl-Met-Leu-Phe (fMLP)-stimulated rat neutrophils. A novel benzyl indazole compound 2-benzyl-3-(4-hydroxymethylphenyl)indazole (CHS-111), which inhibited O(2)(-) generation and cell migration, also reduced the fMLP- but not phorbol ester-stimulated PLD activity (IC(50) 3.9±1.2μM). CHS-111 inhibited the interaction of PLD1 with ADP-ribosylation factor (Arf) 6 and Ras homology (Rho) A, and reduced the membrane recruitment of RhoA in fMLP-stimulated cells but not in GTPγS-stimulated cell-free system. CHS-111 reduced the cellular levels of GTP-bound RhoA, membrane recruitment of Rho-associated protein kinase 1 and the downstream myosin light chain 2 phosphorylation, and attenuated the interaction between phosphatidylinositol 4-phosphate 5-kinase (PIP5K) and Arf6, whereas it only slightly inhibited the guanine nucleotide exchange activity of human Dbs (DH/PH) protein and did not affect the arfaptin binding to Arf6. CHS-111 inhibited the interaction of RhoA with Vav, the membrane association and the phosphorylation of Vav. CHS-111 had no effect on the phosphorylation of Src family kinases (SFK) but attenuated the interaction of Vav with Lck, Hck, Fgr and Lyn. CHS-111 also inhibited the interaction of PLD1 with protein kinase C (PKC) α, βI and βII isoenzymes, and the phosphorylation of PLD1. These results indicate that inhibition of fMLP-stimulated PLD activity by CHS-111 is attributable to the blockade of RhoA activation via the interference with SFK-mediated Vav activation, attenuation of the interaction of Arf6 with PLD1 and PIP5K, and the activation of Ca(2+)-dependent PKC in rat neutrophils.
一种选择性的磷脂酶 D(PLD)抑制剂 5-氟-2-吲哚基去氯卤代苯并脒(FIPI)抑制了氧自由基(O(2)(-))的产生和细胞迁移,但不抑制甲酰-Met-Leu-Phe(fMLP)刺激的大鼠中性粒细胞脱颗粒。一种新型的苯并吲唑化合物 2-苯甲基-3-(4-羟甲基苯基)吲唑(CHS-111),抑制了氧自由基(O(2)(-))的产生和细胞迁移,也降低了 fMLP-但不佛波酯刺激的 PLD 活性(IC(50) 3.9±1.2μM)。CHS-111 抑制了 PLD1 与 ADP-核糖基化因子(Arf)6 和 Ras 同源(Rho)A 的相互作用,减少了 fMLP 刺激细胞中 RhoA 的膜募集,但不减少 GTPγS 刺激的无细胞体系中的 RhoA 膜募集。CHS-111 降低了细胞内 GTP 结合 RhoA 的水平、Rho 相关蛋白激酶 1 的膜募集和下游肌球蛋白轻链 2 的磷酸化,并减弱了磷脂酰肌醇 4-磷酸 5-激酶(PIP5K)与 Arf6 的相互作用,而对人 Dbs(DH/PH)蛋白的鸟嘌呤核苷酸交换活性仅有轻微抑制作用,并且不影响arfaptin 与 Arf6 的结合。CHS-111 抑制了 RhoA 与 Vav 的相互作用、Vav 的膜结合和磷酸化。CHS-111 对 Src 家族激酶(SFK)的磷酸化没有影响,但减弱了 Vav 与 Lck、Hck、Fgr 和 Lyn 的相互作用。CHS-111 还抑制了 PLD1 与蛋白激酶 C(PKC)α、βI 和βII 同工酶的相互作用以及 PLD1 的磷酸化。这些结果表明,CHS-111 抑制 fMLP 刺激的 PLD 活性是由于通过干扰 SFK 介导的 Vav 激活来阻断 RhoA 激活,减弱 Arf6 与 PLD1 和 PIP5K 的相互作用,以及在大鼠中性粒细胞中激活 Ca(2+)-依赖性 PKC。